Candid stewardship of one big open question: management engages seriously with a consequential unresolved outcome
The model's full reasoning — Q2 2016 call → NOWe need to determine if management identifies and seriously engages with one consequential operational outcome that is still unresolved. The call discusses several initiatives: Piedmont acquisition, Latin America sale, coal ash closure, renewable projects, pipeline projects, etc. The question asks for ONE specific undertaking already in motion with outcome unknown, discussed with candor and operational specificity. Looking at the transcript, management discusses the Piedmont acquisition: they mention settlement agreements, hearing, integration efforts, closing by end of year. They say "we remain confident of closing the transaction by the end of this year and possibly earlier." That seems fairly confident but not guaranteed. However, they don't go into deep operational specifics about what's going well or not proven. They mention integration efforts are going well. The Latin America sale: they say "progressing as we expected. We are targeting an announcement by the end of the year and believe closing is a 2017 event." They mention strong interest, invited bidders for due diligence. They don't discuss specific challenges or what would make it succeed or fall short. They also mention impairment due to increased probability of sale. Coal ash: they discuss legislation, costs, recovery, but that's more of a regulatory/legal matter, not an operational undertaking with a clear outcome. The most consequential undertaking might be the Piedmont acquisition or the Latin America sale. But does management treat it as genuinely open? They express confidence but also acknowledge uncertainty about timing. However, they don't provide concrete operational details about progress, risks, or what would make it succeed. They say "integration efforts are going well" but no specifics. The question asks for "visible candor and operational specificity: explaining what is going well and what is not yet proven, what the company is doing about it right now, and what would make it succeed or fall short." Management does not seem to provide that level of detail. They are more high-level. Also, the call covers many topics, but the question asks for ONE specific undertaking. The most likely candidate is the Piedmont acquisition, but the discussion is brief and lacks deep operational specifics.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| MMLP | Martin Midstream Partners L.P. | Q2 2024 | 2024-07-18 | B |
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| SNV | Synovus Financial Corp. | Q1 2024 | 2024-04-18 | B |
| CLGN | CollPlant Biotechnologies Ltd. | Q4 2023 | 2024-04-04 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ORGO | Organogenesis Holdings Inc. | Q4 2022 | 2023-03-01 | C |
| TWLO | Twilio Inc. | Q4 2022 | 2023-02-15 | D |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| REGN | Regeneron Pharmaceuticals, Inc. | Q4 2022 | 2023-02-03 | C |
| CUE | Cue Biopharma, Inc. | Q3 2022 | 2022-11-14 | D |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| AKBA | Akebia Therapeutics, Inc. | Q3 2021 | 2021-11-09 | C+ |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| AX | Axos Financial, Inc. | Q4 2021 | 2021-07-29 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| UAA | Under Armour, Inc. | Q3 2017 | 2017-10-31 | F |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DHX | DHI Group, Inc. | Q2 2017 | 2017-07-28 | D |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| TPB | Turning Point Brands, Inc. | Q1 2017 | 2017-05-11 | B |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| MRIN | Marin Software Incorporated | Q4 2016 | 2017-02-28 | D |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| FIBK | First Interstate BancSystem, Inc. | Q4 2016 | 2017-01-27 | B+ |
| SUPN | Supernus Pharmaceuticals, Inc. | Q3 2016 | 2016-11-18 | D |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| SOHO | Sotherly Hotels Inc. | Q3 2016 | 2016-11-08 | D |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| CRIS | Curis, Inc. | Q1 2016 | 2016-05-09 | C |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
TACT · Q4 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management seriously engaging with the large QSR rollout as a specific, already-in-motion undertaking whose outcome remains open. Bart describes it as an ongoing testing and implementation process that has taken over two years, with the company expecting it to begin rolling out in the second half of 2023 (mid-to end of Q3 through Q4) if testing succeeds. He notes recent new orders coming in during Q1, acknowledges the process has had “starts and stops,” and frames success around whether testing goes right and whether the pipeline continues to convert. Steve adds that the rollout will drive significant FST growth in 2024 2023. This is treated as genuinely uncertain rather than assured, with concrete operational details on current progress (new orders, testing), remaining risks (testing outcome, integration), and actions being taken (staying close to the customer, filling the pipeline).
FLUX · Q2 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management actively engaging with the unresolved outcome of scaling production to fulfill the record $31.4 million backlog while restoring gross margins, a specific undertaking already in motion through lean manufacturing, second-shift ramp (launching this month), Mexico sourcing, design cost reductions, and aggressive supplier negotiations. They describe concrete progress (weekly orders, production throughput improvements, quality initiatives) alongside acknowledged risks (chip and component shortages, delayed price effects, inventory commitments), explain current actions (vendor metrics, alternate suppliers, ERP changes), and outline success factors (higher-margin large-pack mix, reduced overstocking).
UAA · Q3 2017 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED — a specific, identifiable thing already in motion... whose result is...YES The transcript shows management identifying the ERP system implementation (launched July 1) as a specific, already-in-motion operational outcome whose result remains unresolved. They detail concrete progress (system now stable, service levels improving) and current actions (ongoing change management with vendors and workforce, fine-tuning through Q4 into 2018), while openly noting residual impacts on shipments and productivity that will not fully resolve until later in the year. This is framed as a genuine risk to Q4 and full-year results rather than a guaranteed success, with visible operational specificity on what is working and what remains unproven.